Siobhán E. Dunphy

Siobhán E. Dunphy

Auto-generated profile, based on publicly available information

Siobhán E. Dunphy

Institute for Science and Technology in Medicine, School of Medicine, Keele University, Stoke-on-Trent, Nottingham ST4 7QB, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2014 in Stem Cells
Verified
Journal Article
Open access
PDF file
LSLaura E. Sidney
Laura E. Sidney
MBMatthew J. Branch
Matthew J. Branch
SDSiobhán E. Dunphy
Siobhán E. Dunphy
HDHarminder S. Dua
Harminder S. Dua
AHAndrew Hopkinson
Andrew Hopkinson
CD34 is a transmembrane phosphoglycoprotein, first identified on hematopoietic stem and progenitor cells. Clinically, it is associated with the selection and enrichment of hematopoietic stem cells for bone marrow transplants. Due to these historical and clinical associations, CD34 expression is almost ubiquitously related to hematopoietic cells, and it is a common misconception that CD34‐positive (CD34+) cells in nonhematopoietic samples represent hematopoietic contamination. The prevailing school of thought states that multipotent mesenchymal stromal cells (MSC) do not express CD34. However, strong evidence demonstrates CD34 is expressed not only by MSC but by a multitude of other nonhematopoietic cell types including muscle satellite cells, corneal keratocytes, interstitial cells, epithelial progenitors, and vascular endothelial progenitors. In many cases, the CD34+ cells represent a small proportion of the total cell population and also indicate a distinct subset of cells with enhanced progenitor activity. Herein, we explore common traits between cells that express CD34, including associated markers, morphology and differentiation potential. We endeavor to highlight key similarities between CD34+ cells, with a focus on progenitor activity. A common function of CD34 has yet to be elucidated, but by analyzing and understanding links between CD34+ cells, we hope to be able to offer an insight into the overlapping properties of cells that express CD34. Stem Cells 2014;32:1380–1389

Verified
Journal Article
Open access
PDF file
SWSamantha Wilson
Samantha Wilson
LSLaura E. Sidney
Laura E. Sidney
SDSiobhán E. Dunphy
Siobhán E. Dunphy
JRJames Rose
James Rose
AHAndrew Hopkinson
Andrew Hopkinson
The worldwide limited availability of suitable corneal donor tissue has led to the development of alternatives, including keratoprostheses (Kpros) and tissue engineered (TE) constructs. Despite advances in bioscaffold design, there is yet to be a corneal equivalent that effectively mimics both the native tissue ultrastructure and biomechanical properties. Human decellularized corneas (DCs) could offer a safe, sustainable source of corneal tissue, increasing the donor pool and potentially reducing the risk of immune rejection after corneal graft surgery. Appropriate, human-specific, decellularization techniques and high-resolution, non-destructive analysis systems are required to ensure reproducible outputs can be achieved. If robust treatment and characterization processes can be developed, DCs could offer a supplement to the donor corneal pool, alongside superior cell culture systems for pharmacology, toxicology and drug discovery studies.

1 October 2014 in Journal of the Mechanical Behavior of Biomedical Materials
Verified
Journal Article
Closed access
SDSiobhán E. Dunphy
Siobhán E. Dunphy
JBJessica A.J. Bratt
Jessica A.J. Bratt
KAKhondoker Akram
Khondoker Akram
Nicholas ForsythNicholas Forsyth
Nicholas Forsyth
AHAlicia J. El Haj
Alicia J. El Haj